Now showing items 1-6 of 6
The high prevalence of substance use disorders among recent MDMA users compared with other drug users: Implications for intervention.
(Addictive behaviors, 2009-08)
In light of the resurgence in MDMA use and its association with polysubstance use, we investigated the 12-month prevalence of substance use disorders (SUDs) among adult MDMA users to determine whether they are at risk of ...
Hallucinogen use disorders among adult users of MDMA and other hallucinogens.
(The American journal on addictions, 2008-09)
We investigated the prevalence, patterns, and correlates of past-year DSM-IV hallucinogen use disorders (HUDs) among past-year users of MDMA and other hallucinogens from a sample of Americans 18 or older (n = 37,227). Users ...
Problem drinking and low-dose naltrexone-assisted opioid detoxification.
(Journal of studies on alcohol and drugs, 2011-05)
OBJECTIVE:The influence of alcohol use on opioid dependence is a major problem that warrants a search for more effective treatment strategies. The addition of very-low-dose naltrexone (VLNTX) to methadone taper was recently ...
Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.
(Journal of clinical psychopharmacology, 2007-10)
BACKGROUND: The clinical use of naltrexone (NTX) in the treatment of opioid dependence has been limited because of poor compliance and inconsistent outcomes. In particular, the therapeutic benefit of extended treatment with ...
Early outcomes following low dose naltrexone enhancement of opioid detoxification.
(The American journal on addictions, 2009-03)
Although withdrawal severity and treatment completion are the initial focus of opioid detoxification, post-detoxification outcome better defines effective interventions. Very low dose naltrexone (VLNTX) in addition to methadone ...
The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.
(The American journal of drug and alcohol abuse, 2012-05)
The management of withdrawal absorbs substantial clinical efforts in opioid dependence (OD). The real challenge lies in improving current pharmacotherapies. Although widely used, clonidine causes problematic adverse effects ...